NCT00003641 2026-02-25
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
Clinical Trials
21 trialsNCT00003027 2023-06-22
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003444 2023-06-22
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00897520 2017-05-19
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
Eastern Cooperative Oncology Group
Completed
NCT00026221 2016-03-17
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006237 2015-03-25
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
SWOG Cancer Research Network
Phase 3 Completed
NCT02074605 2014-02-28
Cognitive Effects of Interferon in Patients With Melanoma
University of Arizona
Completed
NCT00004196 2014-01-20
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
University of Alabama at Birmingham
Phase 3 Completed
NCT00002767 2014-01-06
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002892 2013-12-19
Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00026520 2013-06-24
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00447356 2013-05-13
High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma
Hackensack Meridian Health
Phase 3 Withdrawn
NCT00004244 2013-03-21
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002669 2012-07-02
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002763 2011-11-16
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00006385 2011-11-08
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003091 2011-05-12
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00002733 2011-05-11
Biological Therapy in Treating Patients With Metastatic Cancer
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed